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W
hite coat hypertension, which
should be more descriptively
termed“isolatedclinichyperten-
sion” (1), consists of a condition in which
clinic (or ofﬁce) blood pressure is repeat-
edly 140 mmHg systolic or 90 mmHg
diastolic, whereas 24-h mean blood pres-
sure is below its generally accepted upper
limit of normality, i.e., 125/80 mmHg
(1,2). This article will ﬁrst show evidence
from the PAMELA (Pressioni Arteriose
Monitorate E Loro Associazioni) popula-
tion study that isolated clinic hyperten-
sion is associated with a prevalence of
organdamageandariskofcardiovascular
morbidityandmortality,which,although
less than those of patients with in- and
out-of-ofﬁce hypertension, are distinctly
greater than those displayed by truly nor-
motensive subjects. It will then empha-
size that in diabetic subjects, limited
evidence is available on the prevalence of
isolated clinic hypertension as well as on
its association with diabetic-related mi-
crovascularandmacrovasculardisease.In
this context, some speciﬁc difﬁculties ex-
ist, i.e., 1) the uncertainty about whether
the cut-off clinic and ambulatory blood
pressure values to use should (or should
not) be different from those used in non-
diabetic individuals, 2) the small number
of subjects and events in the few studies
that have addressed this issue, and 3) the
confounding effect of factors such as the
duration of diabetes, the extent and type
of blood pressure–lowering treatments,
and the more or less effective blood glu-
cosecontrolwhensubjectswithandwith-
out isolated clinic hypertension are
compared.
It will be concluded, however, that
recommendations on this matter should
take into due account that, in diabetes,
cardiovascular and renal protection are
enhanced by aggressive reductions in
clinic blood pressure (130/80 mmHg)
and that lowering blood pressure is ben-
eﬁcial even when the initial clinic value is
within the normal blood pressure range,
i.e., 130–139 mmHg (2). This scores in
favor of a systematic blood pressure–
lowering intervention in this condition.
CLINICAL SIGNIFICANCE OF
ISOLATED CLINIC
HYPERTENSION IN THE
POPULATION— PAMELA (3,4) is
an observational study on a population
representative of Monza, a town in the
northeast outskirts of Milan. In 2,052
subjects aged 25–74 years, 356 were di-
agnosed as having an isolated clinic hy-
pertension, i.e., a high clinic together
with a normal 24-h average blood pres-
sure (3,4). This represented 8.5% of the
total population as well as 41.8% of the
number of individuals deﬁned as hyper-
tensive because of an elevation in clinic
blood pressure. The isolated clinic blood
pressure condition was not without clin-
icalconsequences.First,theprevalencein
these subjects of echocardiographic left
ventricular hypertrophy amounted to
15%, which was less than the 25% prev-
alence seen in subjects with sustained
(i.e., both clinic and 24-h) hypertension,
butgreaterthanthe4%prevalenceofnor-
motensive individuals (4). Furthermore,
as shown in Fig. 1, over an about 12-year
follow-up, subjects with isolated clinic
hypertension had an incidence of cardio-
vascular and all-cause mortality that was
also intermediate between that of the two
other conditions (3). This was the case
even when combined cardiovascular
morbid (hospital diagnosis) and fatal
events were considered. Compared with
thenormotensivegroup,theage-andsex-
adjusted increase in the risk of a cardio-
vascular event was signiﬁcantly greater in
subjectswithisolatedclinichypertension,
although less than the more marked in-
crease seen in the “sustained” hyperten-
sive group. Similar ﬁndings were
obtained when isolated clinic hyperten-
sion was diagnosed by ofﬁce versus home
blood pressure, which was made possible
by the semiautomatic morning and
eveningself-measurementsofbloodpres-
sure performed by all subjects of the
PAMELA cohort.
MECHANISMS
RESPONSIBLE FOR THE
INCREASED
CARDIOVASCULAR RISK
ASSOCIATED WITH
ISOLATED CLINIC
HYPERTENSION— It has long been
shownthatsubjectswithisolatedclinichy-
pertension exhibit metabolic abnormali-
ties of prognostic signiﬁcance (5).
However, because the association with an
increased incidence of cardiovascular
events had failed to be documented in
some studies (6), the clinical relevance of
this condition remained for a long time
controversial. As shown in Fig. 2, in sub-
jects with isolated clinic hypertension of
the PAMELA cohort, total serum choles-
terol, serum triglycerides, and BMI were
all higher than in normotensive subjects,
whereas serum HDL cholesterol was
lower, the values often being indistin-
guishable from the abnormal ones seen in
“sustained” hypertension (3). This was
the case also for blood glucose and the
prevalence of a metabolic syndrome,
overt diabetes, and an impaired fasting
blood glucose state. Furthermore, as re-
ported above, in subjects with isolated
clinic hypertension, there was a greater
prevalenceofleftventricularhypertrophy
(7),inlinewithevidencefromotherstud-
ies that this condition is associated with
the presence of subclinical organ damage
(6,8,9). Finally, as shown in Fig. 3, am-
bulatory and home blood pressure values
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“truly” normotensive subjects (3). Be-
causetherelationshipbetweenclinic,am-
bulatory, or home blood pressure and the
incidence of cardiovascular events is a
continuous one from low to high values
(10), this argues against the conclusion
that this condition is clinically innocent.
It also suggests that this increased risk
may materialize even in individuals in
whom isolated clinic hypertension is di-
agnosed in the absence of metabolic ab-
normalities or organ damage. Further
supporttothishypothesiscomesfromthe
observation that in subjects with isolated
clinic hypertension, 24-h blood pressure
variability is increased and that this in-
crease has a long-term adverse prognostic
signiﬁcance, independently of 24-h mean
values (11).
ISOLATED CLINIC
HYPERTENSION AND
ANTIHYPERTENSIVE DRUG
TREATMENT— Whether antihyper-
tensive drug treatment has the same fa-
vorable impact in patients with isolated
clinic versus sustained hypertension is an
issue that has been even rarely addressed.
From data obtained in a subgroup of pa-
tients from a trial on treatment of systolic
hypertension, Fagard et al. (12) reported
that, in patients with isolated clinic hy-
pertension, the blood pressure reduction
was limited to clinic blood pressure val-
ues with a decrease in cardiovascular
event rate that was less than that seen in
the group, in which both clinic and am-
bulatory blood pressure were initially el-
evated and then reduced by treatment.
Furthermore,inalargenumberoftreated
hypertensive patients followed for 14
years, Ben-Dov et al. (13) showed that
subjects in whom ambulatory or ambula-
tory plus clinic blood pressure was not
controlled showed the highest mortality
rate, which was lowest in the condition
termed “white-coat uncontrolled hyper-
tension” because control involved ambu-
latory but not clinic blood pressure.
Because isolated clinic hypertension car-
ries a lower level of risk than sustained
hypertension, a lesser beneﬁt in the
former than in the latter condition is pre-
dictable. These results, however, go
somewhat further insofar as they suggest
that cardiovascular protection by antihy-
pertensive drug treatment depends on
ambulatory blood pressure control. They
also imply that concomitant control or
lack of control of clinic blood pressure
may have a lesser importance. However,
because it was based on a relatively small
group of nonrandomized patients, the
study by Fagard et al. (12) had no sufﬁ-
cient statistical power. Furthermore, in
the treated patients of the study of Ben-
Dov et al. (13), the clinic and ambulatory
blood pressure values might have re-
ﬂected the greater or the lesser difﬁculty
of the drugs used to control “in-ofﬁce”
and “out-of-ofﬁce” blood pressure, possi-
bly because of a difference in the baseline
cardiovascular risk. This may be sup-
ported by an internal inconsistency of the
data, i.e., that, although the difference
was not signiﬁcant, the risk of death was
42%lessinthegroupinwhichbothclinic
Figure 1—Left panels: Incidence of cardiovascular (CV) death, cardiovascular events, and all-cause death in normotensive subjects (Ofﬁce N and
24-h N) and in patients with white-coat hypertension (WCH) and sustained hypertension (Ofﬁce H and 24-h H). 24-h, 24-h ambulatory blood
pressure; H, hypertension; N, normotension. Right panels: Hazard ratio (HR), adjusted for age and sex, for cardiovascular death (upper panel),
cardiovascular events (middle panel), and all-cause death (lower panel). Data were collected in the follow-up (12 years) of the PAMELA study.
Reprinted with permission from Mancia et al. (3).
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controlledbytreatmentthaninthewhite-
coat uncontrolled hypertension, in which
clinic blood pressure values remained
elevated.
ISOLATED CLINIC
HYPERTENSION AND
DIABETES— Only few studies have
explored the clinical signiﬁcance of iso-
lated clinic hypertension in diabetes (14–
17),andinalmostallcases,thenumberof
subjects identiﬁed as having this condi-
tion was limited. This led to a small num-
ber of events and opened the results and
conclusions to the risk of chance. The
largest study performed (18) is the one
carried out on 1,207 consecutive hyper-
tensive patients who were followed for an
average of 4 years to determine the risk
of events such as myocardial infarction,
stroke, and sudden cardiac death. Out of
262patientswithtype2diabetes,only56
were found to have an isolated clinic hy-
pertensionbasedonclinicbloodpressure
values 140/90 mmHg and an average
daytimebloodpressure135/85mmHg.
In the group with isolated clinic hyper-
tension and diabetes, the risk of a cardio-
vascular event was lesser than in the
group with sustained hypertension with-
out or with diabetes. However, it was sur-
prisinglysimilartotheriskofnondiabetic
subjectswithisolatedclinichypertension,
thus apparently denying the well-known
prognostic importance of diabetes per se
atallbloodpressurevalues(19).Thispar-
adoxical ﬁnding may have resulted from
the low number of events in the various
groups. In the group with isolated clinic
hypertension and diabetes, for example,
during the follow-up, there were only
4.2% of the 97 recorded events, i.e., four
events in all.
An additional set of data provided by
the PAMELA study may be of interest
(20). Independently from use of antihy-
pertensivedrugs,insubjectswithisolated
clinic hypertension, the 10-year risk of
developinganew-onsetdiabeteswas2.89
Figure 3—Ofﬁce systolic blood pressure (SBP) in normotensive (N) and white-coat hypertensive
(WCH)patientsasdeﬁnedbyanelevationinofﬁceversus24-hSBP(leftpanel)orinofﬁceversus
home SBP (right panel). Reprinted with permission from Mancia et al. (3).
Figure2—ValuesofBMI,totalcholesterol(Chol),triglycerides,HDLcholesterol,andplasmaglucoseinnormotensive(N),white-coathypertensive
(WCH),andsustainedhypertensive(H)ofthePAMELAstudy.Prevalenceofmetabolicsyndrome(MS),diabetes(DM),andimpairedfastingglucose
(IFG) in the three groups of patients are also shown. Data are superimposable when the diagnosis of the three blood pressure states is based on ofﬁce
versus24-hambulatorybloodpressuremonitoringoronofﬁceversushomebloodpressure.*P0.05andreferstothestatisticalsigniﬁcancebetween
groups. Reprinted with permission from Mancia et al. (3).
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(95% CI 1.34–6.22, P  0.007), the in-
crease being similar to that of sustained
hypertensive patients. Furthermore, the
risk of developing an impaired fasting
glucose state in subjects with an initial
blood glucose 100 mg/dl was about
four times (relative risk 3.72, 95% CI
2.10–6.60, P  0.001) greater in the iso-
lated clinic hypertensive subjects than in
the normotensive group. Thus, subjects
with isolated clinic hypertension have a
much greater chance of developing high
cardiovascular risk conditions such as
pre-diabetes and diabetes over the years
following identiﬁcation of their abnormal
blood pressure pattern. This is further
reason not to take this identiﬁcation
lightly.
CONCLUSIONS— Thelimitedamount
ofdataavailableonisolatedclinichyperten-
sion and diabetes should not divert atten-
tion from the large body of evidence that
diabetespersecarriesahighcardiovascu-
lar risk (19) and that antihypertensive
treatmenthascardiovascularandnephro-
protective effects (21,22) when initial
blood pressure is well below the values
thattraditionallydeﬁneisolatedclinichy-
pertension (2). It should also be remem-
bered that the ﬁnding that low blood
pressure is protective against diabetes-
relatedmicrovascularcomplicationshasa
pathophysiological explanation. In those
with diabetes, there is an early loss of
small artery autoregulation (23), which
exposes microcirculation to a higher
blood pressure than that of nondiabetic
subjects, favoring rather than damaging
the vessel wall. This calls for antihyper-
tensive drug treatment also in diabetic
subjectswithisolatedclinichypertension.
Nevertheless,tryingtodeﬁnetheriskand
the beneﬁt of treatment in this condition
vis a ` vis those of sustained hypertensives
is valuable because it may allow to distin-
guish categories of patients in whom
treatment and blood pressure goals
should be more or less aggressive.
However, the studies addressing this
issue will have to overcome several prob-
lems. The ﬁrst problem is whether the
cutoffclinicbloodpressurevaluesusedto
diagnose isolated clinic hypertension in
the general hypertensive population hold
for diabetic subjects, in whom the thresh-
old for antihypertensive drug treatment
(andthustheoperationaldeﬁnitionofhy-
pertension) is 130/80 mmHg rather than
140/90mmHg(2).Whethercutoffambu-
latory blood pressure values should also
be different in diabetic and nondiabetic
subjects is another important question. It
is relevant to this issue that in diabetic
subjects the nocturnal blood pressure de-
cline undergoes an early attenuation (24)
caused by early subclinical dysautonomia
(25), making the average 24-h values rel-
atively higher than those for nondiabetic
subjects with preserved nocturnal hypo-
tension. Future studies will require a
larger number of events to provide con-
clusions that have sufﬁcient statistical
power.Thestudieswillalsorequireprop-
erlymatchedgroupsforfactorsimportant
for patient prognosis, such as duration of
diabetes, achieved blood pressure con-
trol, and type of antihypertensive drugs
used, given their differential importance
for protection against diabetes-related
cardiovascular complications (2). Match-
ing should also be sought for the magni-
tude of nocturnal blood pressure decline
because nighttime blood pressure is a
more sensitive predictor of patient out-
come than daytime blood pressure
(10,26,27). Failure to take this into ac-
count may lead to the recruitment of
higher-risk patients in the sustained hy-
pertension group (in which nocturnal
bloodpressuredeclineismorelikely),en-
dangering the demonstration of the dif-
ferent effects of treatment in the two
conditions.
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